<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017550</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068709</org_study_id>
    <secondary_id>SMC-101-1020</secondary_id>
    <secondary_id>RUSH-MDS-2000-04</secondary_id>
    <nct_id>NCT00017550</nct_id>
  </id_info>
  <brief_title>Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be&#xD;
      effective treatment for myelodysplastic syndrome. It is not yet known whether&#xD;
      immunosuppressive therapy is more effective than supportive care in treating myelodysplastic&#xD;
      syndrome.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of antithymocyte globulin&#xD;
      with that of supportive care in treating patients who have myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the clinical response rate of patients with early myelodysplastic syndrome&#xD;
           treated with rabbit anti-thymocyte globulin vs standard supportive care.&#xD;
&#xD;
        -  Evaluate the safety of anti-thymocyte globulin in these patients.&#xD;
&#xD;
        -  Compare the time to and duration of clinical response, rates of partial response and&#xD;
           therapy failure, and rate of disease progression in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the ECOG performance score, number of transfusions and/or growth factor use, and&#xD;
           maximum time between transfusions in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the infection risk, use of medical resources, and quality of clinical response&#xD;
           in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to myelodysplastic syndrome (MDS) subtype (refractory anemia (RA) vs RA with excess&#xD;
      blasts or hypocellular MDS). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive rabbit anti-thymocyte globulin (ATG) IV over at least 8-12 hours&#xD;
           on days 1-4.&#xD;
&#xD;
        -  Arm II: Patients receive standard supportive therapy for 6 months. At the end of 6&#xD;
           months, patients may receive ATG as in arm I.&#xD;
&#xD;
      Patients are followed for 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 72 patients (48 in arm I and 24 in arm II) will be accrued&#xD;
      within a minimum of 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2000</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed early myelodysplastic syndrome (MDS) with&#xD;
             less than 10% bone marrow blasts&#xD;
&#xD;
               -  Refractory anemia (RA)&#xD;
&#xD;
               -  RA with excess blasts (RAEB)&#xD;
&#xD;
               -  Hypocellular myelodysplasia&#xD;
&#xD;
          -  Low or intermediate-1 prognostic risk&#xD;
&#xD;
          -  Transfusion-dependent&#xD;
&#xD;
               -  Need for 2 or more units of red blood cells or platelets per month for 2 or more&#xD;
                  months prior to study OR&#xD;
&#xD;
               -  History of prior transfusions and 2 consecutive (at least 21 days apart)&#xD;
                  hemoglobin levels less than 8.0 g/dL or platelet counts less than 20,000/mm^3&#xD;
                  during the past 2 months&#xD;
&#xD;
                    -  Hemoglobin no greater than 12.0 g/dL after prior transfusion&#xD;
&#xD;
          -  No myelosclerosis occupying more than 30% of bone marrow space&#xD;
&#xD;
          -  No RA with ringed sideroblasts, RAEB in transformation, or chronic myelomonocytic&#xD;
             leukemia&#xD;
&#xD;
          -  No therapy-related MDS&#xD;
&#xD;
          -  No history of immune-related hematologic disorder (e.g., idiopathic thrombocytopenic&#xD;
             purpura)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other causes of cytopenia unrelated to MDS (e.g., gastrointestinal blood loss)&#xD;
&#xD;
          -  Iron present on marrow examination OR&#xD;
&#xD;
          -  Transferrin saturation at least 20% and ferritin at least 50 ng/mL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL OR&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2 times normal&#xD;
&#xD;
          -  No active or chronic hepatitis B or C&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic cardiac disease&#xD;
&#xD;
          -  No congestive heart failure (even if medically controlled)&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe pulmonary disease&#xD;
&#xD;
          -  If history of pulmonary insufficiency, must have pO_2 at least 90 mm/Hg on room air or&#xD;
             pCO_2 no greater than 40 mm/Hg&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of unresolved B12 or folate deficiency since diagnosis of MDS&#xD;
&#xD;
          -  No untreated acute or chronic infection (afebrile for 7 days without antibiotics prior&#xD;
             to study)&#xD;
&#xD;
          -  No active or chronic HIV&#xD;
&#xD;
          -  No concurrent cytomegalovirus infection&#xD;
&#xD;
          -  No other malignancy within the past 2 years except adequately treated localized&#xD;
             squamous cell or basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No concurrent drug or alcohol abuse&#xD;
&#xD;
          -  No significant medical or psychosocial problems&#xD;
&#xD;
          -  No known allergy to rabbit protein&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 8 weeks since prior biologic agents, colony-stimulating factors, or epoetin&#xD;
             alfa for MDS&#xD;
&#xD;
          -  At least 8 weeks since other prior investigational biologic agents&#xD;
&#xD;
          -  No prior or concurrent bone marrow transplantation&#xD;
&#xD;
          -  No concurrent epoetin alfa&#xD;
&#xD;
          -  No concurrent growth factors except filgrastim (G-CSF) or sargramostim (GM-CSF) for&#xD;
             neutropenic fevers&#xD;
&#xD;
          -  No other concurrent biologic agents&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 8 weeks since prior cytotoxic drugs for MDS&#xD;
&#xD;
          -  Concurrent chemotherapy for clinical indications of disease progression or leukemic&#xD;
             transformation allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 8 weeks since prior androgenic hormonal therapy for MDS&#xD;
&#xD;
          -  At least 8 weeks since prior danazol for MDS&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior organ transplantation&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 8 weeks since prior investigational drugs&#xD;
&#xD;
          -  At least 8 weeks since prior immunosuppressive drugs or other drugs for MDS&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth C. Squiers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sangstat Medical Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Cancer Center, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Tampa (Haley)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Cancer Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplant</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-2539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Cornell Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230-2503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

